

# INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

## MEETING MINUTES

**Meeting Date:** Thursday, February 19, 2026  
**Time:** 1:00 pm Eastern Time  
**Location:** Zoom Teleconference  
**Institution:** BriaCell Therapeutics Corp., Philadelphia, PA  
**Principal Investigator:** Ying Liu, PhD, MS  
**Project:** BriaCell Therapeutics, Corp., Bria- 1A/B  
**Meeting Type:** Initial Review of Project and Site  
**Title:** Creation, Testing, and Use of Lentiviral Vectors for Tumor Cell Engineering

### 1. Call to order:

The Meeting was called to order at 1:01 pm Eastern Time.

### 2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

### 3. Declaration of quorum:

Four voting members were present, including two local members unaffiliated with the institution. Also present were the Principal Investigator, four Institutional Representatives, and IBC Services staff. The Chair declared that a quorum was present.

### 4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

### 5. Public posting:

An Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

### 6. Review of proposed research:

The Chair provided an overview of the project. The Committee had no questions or concerns.

### 7. Determination for biosafety level and period of IBC oversight:

The Committee determined that **BSL-2 containment facilities and practices** are required for all work with human cells and replication-defective lentiviral vectors.

The Committee determined that **BSL-2+ containment facilities and practices** are required for the creation of lentiviral vectors and replication competency testing, including the use of R8.71. BSL-2+ includes the use of double gloves, autoclaving of materials prior to disposal, and storage in a dedicated locked freezer.

The Committee determined that **IBC oversight will continue as long as the research is active at the site.**

### 8. Vote on project:

The Committee voted for following determination on the Project:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 4

NO: 0

ABSTAIN: 0

### 9. Review of Principal Investigator Qualifications:

The Committee reviewed and accepted the qualifications of the Principal Investigator.

## INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

### **10. Review of proposed facilities and practices:**

The Chair provided an overview of the arrangement for the facilities and practices.

#### **Points of Discussion:**

1. The Committee recommended that the BSL-2+ biohazard sign be revised to include double gloves and that PPE requirements be written on all biohazard signs.
2. The Principal Investigator stated the following regarding locations:
  - a. The Storage freezers are in room 342 and are accessible via badge only
  - b. The autoclave is in room 341 and will be used to decontaminate BSL-2+ waste prior to disposal
  - c. Biohazardous waste is stored in room 339 prior to collection by the waste hauler
3. The Committee recommended that site documents, including the site map, Site Inspection Checklist, and photos, be revised to indicate the locations above.
4. The Committee recommended that photos of the transport container, posted biohazardous waste signage, and the inside of room 339 be provided to IBC Services.
5. The Committee recommended that the autoclave be labelled with a biohazard symbol and that the autoclave addendum be completed and provided to IBC Services.
6. The Committee recommended that sinks and eyewashes be indicated on the site map.
7. The Principal Investigator confirmed that the research does not involve needles or injections.
8. The Committee recommended that the institution follow up with IBC Services on whether room 339 is negatively pressurized.
9. The Committee noted that the research involves potentially infectious material and that an Exposure Control Plan (ECP) must be in place per OSHA regulations. The Principal Investigator confirmed that an ECP is in place and that staff training is ongoing. The Committee recommended that Site Inspection Checklist (#3) be revised to indicate this.
10. The Committee recommended that a spill kit be created for cleaning of large spills.

### **11. Site responsibilities:**

The Chair reviewed training and communication requirements for maintaining IBC approval with the Institutional Representatives and Principal Investigator.

### **12. Vote on the site:**

The Committee voted for following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 4

NO: 0

ABSTAIN: 0

### **13. Advice to Institution:** None.

**14. Meeting adjourned:** The meeting was adjourned at 1:47 pm Eastern Time.

**15. Post-Meeting Notes:** None.

### **Documents Reviewed:**

Agenda

BriaCell, Abstracts, received 12-31-2025

BriaCell Project 1A, Summary and list of biological materials, received 12-31-2025

BriaCell Project 1B, Summary and list of biological materials, received 12-31-2025

Additional Information, Cell Products and Transgenes, received 02-11-2026

Environmental Health and Safety Manual, dated 2025

Lab Protocol, received 12-23-2025

BriaCell Therapeutics, Corp./Bria-1A/B/Liu/2/19/2026/Initial Review

## INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

Site Map, dated 01-26-2026  
Site Inspection Checklist, dated 01-26-2026  
Photos, dated 01-16-2026  
Biohazard Signage, dated 01-27-2026  
Biological Safety Cabinet Certifications, dated 12-2025, 01-2026  
SOP, Ultracentrifuge, received 12-23-2025  
SOP, Transduction of Lentivirus, received 12-23-2025  
SOP, Spinoculation of PBMC with Lentivirus Vector, received 12-23-2025  
SOP, Quantify Lentiviral Associated p24 in Lentivirus Medium by ELISA, received 12-23-2025  
SOP, Produce Lentivirus and Quality Test, received 12-23-2025  
SOP, Laboratory, received 12-23-2025  
Training, Shipping Certifications, dated 01-2026  
CV, Liu, Y., received 12-23-2025